CORDIS · 305853 · FP7
TRAUMAKINE Interferon-beta treatment of acute respiratory distress syndrome (ARDS)
Coordinator: FARON PHARMACEUTICALS OY (FI)
This application aims at a European marketing application for an orphan indication of the biopharmaceutical interferon-beta (IFN-beta) (EU3/07/505), to treat acute lunge injury (ALI) and acute respiratory distress syndrome (ARDS). Despite the much improved mechanical ventilation techniques and improved supportive therapies, ARDS kills 35-40 % of the 175.000 annual European patients. This condition has no approved pharmacological treatment in Europe. The applicant, Faron Pharmaceuticals, has recently finished a clinical phase I/II study with ALI/ARDS patients to obtain initial safety and pharm…
About Seventh Framework Programme (2007–2013)
The Seventh Framework Programme (FP7) ran from 2007 to 2013 and was the EU's main research-funding instrument of that period. It mobilised roughly €50 billion across cooperation projects, ERC frontier grants, Marie Curie fellowships, capacity-building actions and Euratom research. FP7 closed to new calls in 2013 but its projects continued for years after under their original grant agreements.
Co-funding: the European Union contributes €6.0M toward a total project budget of €7.8M — a funding rate of 77%, with the remainder covered by the consortium partners. The project runs over approximately 5.5 years from 2012-12-01 to 2018-05-31.
Full record on CORDIS — partners, deliverables, publications, news.
Open on cordis.europa.eu →More from FI
see all →- BalticSeaH2 — Cross-border Hydrogen Valley around the Baltic Sea101112047 · HORIZON · €25.0M
- R4C — Regions4Climate101093873 · HORIZON · €24.5M
- LUMI-IQ — LUMI AI Factory - Advanced experimental AI-optimised quantum based platform101239031 · HORIZON · €20.0M
- SPARCs — Sustainable energy Positive & zero cARbon CommunitieS864242 · H2020 · €19.7M
- Qu-Pilot — Experimental production capabilities for quantum technologies in Europe101113983 · HORIZON · €19.0M
- EUDAT2020 — EUDAT2020654065 · H2020 · €18.9M
Other FP7 projects
see all →- COST II — Provision of Scientific, Technical and Administrative Management of COST200443 · FR · €250.0M
- COMBACTE-NET — Combatting Bacterial Resistance in Europe115523 · SE · €109.4M
- EUC²LID — European Lead Factory115489 · DE · €80.0M
- COMBACTE-MAGNET — Combatting Bacterial Resistance in Europe - Molecules against Gram Negative Infections115737 · SE · €75.3M
- ENABLE — European Gram Negative Antibacterial Engine115583 · UK · €58.9M
- PLACES2BE — Pilot Lines for Advanced CMOS EmbodimentS in 2x nodes, Built in Europe325633 · FR · €52.6M
Frequently asked questions
- Who funds this research project?
- This project is funded by the European Union through the Seventh Framework Programme (2007–2013) programme, under the CP-FP funding scheme.
- What is the EU contribution?
- The European Commission contributes €6.0M toward a total project budget of €7.8M.
- Which EU programme funds it?
- The project is funded under Seventh Framework Programme (2007–2013).
- Who coordinates the project?
- The project is coordinated by FARON PHARMACEUTICALS OY (FI).
- What is the project timeline?
- The project runs from 2012-12-01 to 2018-05-31 — approximately 5.5 years.
- Where can I find the full project record?
- The complete record — partners, deliverables, publications and news — is published on CORDIS under project ID 305853.